UOC
MLYS icon

UBS O'Connor’s Mineralys Therapeutics MLYS Stock Holding History

UBS O'Connor’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-79,723
Closed -$1.08M – 389
2025
Q2 		$1.08M Buy
79,723
+6,375
+9% +$92.4K 0.03% 206
2025
Q1 		$1.16M Buy
73,348
+45,280
+161% +$521K 0.03% 173
2024
Q4 		$346K Sell
28,068
-3,000
-10% -$39.2K 0.01% 305
2024
Q3 		$376K Sell
31,068
-28,863
-48% -$349K 0.01% 361
2024
Q2 		$701K Buy
59,931
+1,457
+2% +$18.4K 0.02% 342
2024
Q1 		$755K Sell
58,474
-127,694
-69% -$1.58M 0.02% 303
2023
Q4 		$1.6M Buy
+186,168
New +$1.46M 0.05% 210

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS O'Connor's MLYS Position: Q3 2025 in Review

UBS O'Connor sold out of Mineralys Therapeutics (MLYS) in Q3 2025, closing a stake of 79,723 shares — an estimated $1.08M sold.

UBS O'Connor first reported a position in MLYS in Q4 2023 and held it in 7 quarters. The position peaked at $1.6M in Q4 2023. 193 funds tracked by Wall St. Rank hold MLYS as of Q3 2025.

  • UBS O'Connor reported no remaining Mineralys Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 79,723 Mineralys Therapeutics shares in Q3 2025, an estimated $1.08M.
  • UBS O'Connor first reported a position in Mineralys Therapeutics in Q4 2023 and held it in 7 quarters.
  • UBS O'Connor's Mineralys Therapeutics position peaked at $1.6M in Q4 2023.
  • 193 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.